Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy
- PMID: 40354673
- DOI: 10.1021/acsabm.5c00489
Nanotechnology-Enhanced siRNA Delivery: Revolutionizing Cancer Therapy
Abstract
RNA interference (RNAi) has emerged as a transformative approach for cancer therapy, enabling precise gene silencing through small interfering RNA (siRNA). However, the clinical application of siRNA-based treatments faces challenges such as rapid degradation, inefficient cellular uptake, and immune system clearance. Nanotechnology-enhanced siRNA delivery has revolutionized cancer therapy by addressing these limitations, improving siRNA stability, tumor-specific targeting, and therapeutic efficacy. Recent advancements in nanocarrier engineering have introduced innovative strategies to enhance the safety and precision of siRNA-based therapies, offering new opportunities for personalized medicine. This review highlights three key innovations in nanotechnology-enhanced siRNA delivery: artificial intelligence (AI)-driven nanocarrier design, multifunctional nanoparticles for combined therapeutic strategies, and biomimetic nanocarriers for enhanced biocompatibility. AI-driven nanocarriers utilize machine learning algorithms to optimize nanoparticle properties, improving drug release profiles and minimizing off-target effects. Multifunctional nanoparticles integrate siRNA with chemotherapy, immunotherapy, or photothermal therapy, enabling synergistic treatment approaches that enhance therapeutic outcomes and reduce drug resistance. Biomimetic nanocarriers, including exosome-mimicking systems and cell-membrane-coated nanoparticles, improve circulation time, immune evasion, and targeted tumor delivery. These innovations collectively enhance the precision, efficiency, and safety of siRNA-based cancer therapies. The scope and novelty of these advancements lie in their ability to overcome the primary barriers of siRNA delivery while paving the way for clinically viable solutions. This review provides a comprehensive analysis of the latest developments in nanocarrier fabrication, preclinical and clinical studies, and safety assessments. By integrating AI-driven design, multifunctionality, and biomimicry, nanotechnology-enhanced siRNA delivery holds immense potential for the future of precision cancer therapy.
Keywords: AI-Driven Nanocarriers; Cancer Therapy; Multifunctional Nanoparticles; Targeted Drug Delivery; siRNA Delivery.
Similar articles
-
Recent advances in PD-L1 siRNA nanocarriers for cancer therapy.Int J Biol Macromol. 2025 Jun;311(Pt 3):143994. doi: 10.1016/j.ijbiomac.2025.143994. Epub 2025 May 6. Int J Biol Macromol. 2025. PMID: 40339860 Review.
-
Precision arrows: Navigating breast cancer with nanotechnology siRNA.Int J Pharm. 2024 Sep 5;662:124403. doi: 10.1016/j.ijpharm.2024.124403. Epub 2024 Jun 27. Int J Pharm. 2024. PMID: 38944167 Review.
-
Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.Adv Healthc Mater. 2014 Aug;3(8):1182-93. doi: 10.1002/adhm.201300607. Epub 2014 Feb 28. Adv Healthc Mater. 2014. PMID: 24577795 Review.
-
AI-driven innovations in smart multifunctional nanocarriers for drug and gene delivery: A mini-review.Crit Rev Oncol Hematol. 2025 Jun;210:104701. doi: 10.1016/j.critrevonc.2025.104701. Epub 2025 Mar 13. Crit Rev Oncol Hematol. 2025. PMID: 40086770 Review.
-
Revolutionizing prostate cancer therapy: Artificial intelligence - Based nanocarriers for precision diagnosis and treatment.Crit Rev Oncol Hematol. 2025 Apr;208:104653. doi: 10.1016/j.critrevonc.2025.104653. Epub 2025 Feb 7. Crit Rev Oncol Hematol. 2025. PMID: 39923922 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical